绥美凯是什么药物呢？

In January 2018, ViiV Healthcare, a joint venture of the British multinational pharmaceutical company GlaxoSmithKline (GSK), officially launched its innovative AIDS treatment drug (Inbec) in the Chinese market.

Inbec is the only three-in-one compound drug containing dolutegravir (DTG), which integrates treatment drugs for different stages of viral infection in the same tablet. Patients only need to take one drug to achieve the effect of combined medication. The drug has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection.

Suimeike is a film-coated tablet that appears white or off-white after the coating is removed. It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B*5701 allele, he should not take products containing abacavir.

For adults and adolescents (weighing not less than 40kg), the recommended dosage of SuimeiKai is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced. Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.

Comparing it with the other two integrase inhibitor first-line regimens of RAL (Ascent) and EVG (elvitegravir) in patients who failed treatment, (Inbec) has significantly fewer drug-resistant mutation sites than the other two drugs, making it less likely to develop resistance.